H
Harry Shi
Researcher at Pfizer
Publications - 22
Citations - 3793
Harry Shi is an academic researcher from Pfizer. The author has contributed to research in topics: Eplerenone & Heart failure. The author has an hindex of 14, co-authored 19 publications receiving 3302 citations.
Papers
More filters
Journal ArticleDOI
Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms
Faiez Zannad,John J.V. McMurray,Henry Krum,Dirk J. van Veldhuisen,Karl Swedberg,Harry Shi,John Vincent,Stuart J. Pocock,Bertram Pitt +8 more
TL;DR: Eplerenone, as compared with placebo, reduced both the risk of death and therisk of hospitalization among patients with systolic heart failure and mild symptoms.
Journal ArticleDOI
Eplerenone and atrial fibrillation in mild systolic heart failure: Results from the EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization and SurvIval Study in Heart Failure) study
Karl Swedberg,Faiez Zannad,John J.V. McMurray,Henry Krum,Dirk J. van Veldhuisen,Harry Shi,John Vincent,Bertram Pitt +7 more
TL;DR: In patients with systolic heart failure and mild symptoms, eplerenone reduced the incidence of new onset AFF, and the effects of eplerene on the reduction of major CV events were similar in patients with and without AFF at baseline.
Journal ArticleDOI
Eplerenone in patients with systolic heart failure and mild symptoms: analysis of repeat hospitalizations.
Jennifer K. Rogers,John J.V. McMurray,Stuart J. Pocock,Faiez Zannad,Henry Krum,Dirk J. van Veldhuisen,Karl Swedberg,Harry Shi,John Vincent,Bertram Pitt +9 more
TL;DR: The Eplerenone in Mild Patients Hospitalization and SurvIval Study in Heart Failure (EMPHASIS-HF) trial as mentioned in this paper showed that the Eplrenone significantly reduced the risk of heart failure hospitalization in patients with mild symptoms to a greater extent than is captured by only studying the first hospitalization.
Journal ArticleDOI
Safety and Efficacy of Eplerenone in Patients at High Risk for Hyperkalemia and/or Worsening Renal Function : Analyses of the EMPHASIS-HF Study Subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure)
Romain Eschalier,John J.V. McMurray,John J.V. McMurray,Karl Swedberg,Dirk J. van Veldhuisen,Henry Krum,Stuart J. Pocock,Harry Shi,John Vincent,Patrick Rossignol,Faiez Zannad,Bertram Pitt,Emphasis-Hf Investigators +12 more
TL;DR: In patients with chronic HF-REF, in NYHA functional class II, and meeting specific inclusion and exclusion criteria, eplerenone was both efficacious and safe when carefully monitored, even in subgroups at high risk of developing hyperkalemia or WRF.
Journal ArticleDOI
Incidence, Determinants, and Prognostic Significance of Hyperkalemia and Worsening Renal Function in Patients With Heart Failure Receiving the Mineralocorticoid Receptor Antagonist Eplerenone or Placebo in Addition to Optimal Medical Therapy Results From the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF)
Patrick Rossignol,Daniela Dobre,John J.V. McMurray,Karl Swedberg,Henry Krum,Dirk J. van Veldhuisen,Harry Shi,Michael Messig,John Vincent,Nicolas Girerd,George L. Bakris,Bertram Pitt,Faiez Zannad +12 more
TL;DR: The Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF) as discussed by the authors assessed the risk factors for mineralocorticoid receptor antagonist-related renal function (WRF) and hyperkalemia (HK), as well as the association between HK and WRF with clinical outcomes.